SmartTRAK interviews Suneet Varma, CEO of INTENT Biologics, to discuss the company’s novel exosome technology for advanced wound care.
In this interview, the CEO of INTENT Biologics details how Purified Exosome Product (PEP), a high-potency exosome therapy, achieved a remarkable 0% recurrence rate in Phase II wound care trials for diabetic foot ulcers (DFUs). Discover the science behind why this acellular alternative is poised to expand the options for treating DFUs and other chronic wounds.
Interview Transcript:
SmartTRAK: My name's Elizabeth Anderson. I'm with SmartTRAK, and today I'm speaking with Suneet Varma, who is currently a senior advisor for RION Therapeutics and also CEO of INTENT Biologics. This is a very interesting space that they're in and developing the exosomes, and they are looking into just finishing up a Phase II trial for diabetic foot ulcers. Today, we're going to talk a little bit about exosomes, their role in the marketplace and his thoughts on bringing this product to the market, so welcome.
Can you tell us a little bit about the genesis of the exosomes, the plasma-derived exosomes, and talk a little bit about the genesis and this coming out of the Mayo Clinic?
SV: Very exciting. More than a decade ago, two physicians from the Mayo Clinic, Dr. Atta Behfar and Dr. Andre Terzic, made a discovery as part of the regenerative medicine center at Mayo that exosomes, not stem cells, are regenerative. In other words, exosomes are the material within our body. They're the messengers between cells and their function is really determined from whence they came.
RION essentially took the mantle forward of, ‘How do I now develop these exosomes into other uses in the healthcare environment?’ RION was formed with that purpose and started to develop exosomes and made further discoveries ...
Want to learn more about INTENT Biologics novel exosome technology for advanced wound care? Click the button below to download and read the complete transcript of our interview with Suneet Varma conducted by Elizabeth Anderson, SmartTRAK Senior Analyst.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
